Steroidogenic abnormalities in ovarian theca cells in polycystic ovary syndrome

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 6, 2002, Pages 486-491

  Wickenheisser, Jessica K ^a   Strauss III, Jerome F ^b   McAllister, Jan M ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYPREGNENOLONE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); GESTAGEN; HYDROXYPROGESTERONE; INHIBIN; INHIBIN B; INSULIN RECEPTOR SUBSTRATE 2; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; PRASTERONE; PREGNENOLONE; PROGESTERONE; STEROID; STEROID 17ALPHA MONOOXYGENASE; STEROIDOGENIC ACUTE REGULATORY PROTEIN;

ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; CELL ACTIVITY; CELL ASSAY; CELL ISOLATION; CHOLESTEROL TRANSPORT; DEGRADATION; DNA POLYMORPHISM; GENE EXPRESSION; GENE FUNCTION; GRANULOSA CELL; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOTHESIS; INSULIN RESISTANCE; OVARY CELL; OVARY CELL CULTURE; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PROGESTERONE SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR SENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; THECA CELL;

EID: 0037672623     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200212000-00008     Document Type: Review

References (69)

1. Legro RS: Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Mol Cell Endocrinol 1998, 145:103-110.
2. Franks S, Gharani N, Waterworth D, et al.: The genetic basis of polycystic ovary syndrome. Hum Reprod 1997, 12:2641-2648.
3. Goldzieher J: Polycystic ovarian disease. Fertil Steril 1981, 35:371-394.
4. Barnes R, Rosenfield R: The polycystic ovary syndrome. Ann Intern Med 1989, 110:386-399.
5. Yen S: The polycystic ovary syndrome. Clin Endocrinol 1980, 12:177-207.
6. Goldzieher J, Green J: The polycystic ovary. Clinical and histologic features. J Clin Endocrinol Metab 1962, 22:325-338.
7. Erickson G, Magoffin D, Dyer C, et al.: The ovarian androgen producing cells: a review of structure/function relationships. Endocrinol Rev 1985, 6:371-399.
8. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774-800.
9. Carmina E, Lobo R: Polycystic ovary syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999, 84:1897-1899.
10. Strauss J, Dunaif A: Molecular mysteries of polycystic ovary syndrome. Mol Endocrinol 1999, 13:800-805.
11. Legro R, Driscoll D, Strauss III J, et al.: Evidence for a genetic basis for hy perandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci (USA) 1998, 95:14956-14960.
12. Carey A, Waterworth D, Patel K, et al.: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Gen 1994, 3:1873-1876.
13. Ben-Shlomo I, Franks S, Adashi E: The polycystic ovary syndrome: nature or nuture. Fertil Steril 1995, 63:953-954.
14. Nelson V, Legro R, Strauss J, et al.: Augmented androgen production is a stable phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999, 13:946-957. This report documents that increased androgen biosynthesis is a stable phenotype of PCOS theca cells propagated in long-term culture, and correlates with elevated CYP17 and CYP11A gene expression.
15. Doody K, Lorence M, Mason J, et al.: Expression of mRNA species encoding steroidogenic enzymes in human follicles and corpora lutea throughout the menstrual cycle. J Clin Endocrinol Metab 1990, 70:1041-1045.
16. McNatty K, Makris A, DeGrazia O, et al.: The production of progesterone, androgens and estrogens by granulosa cells, thecal tissue, and stromal tissue from human ovaries in vitro. J Clin Endocrinol Metab 1979, 49:687-699.
17. Moon Y, Tsang B, Simpson C, et al.: 17β-Estradiol biosynthesis in cultured granulosa and thecal cells of human ovarian follicles; stimulation by follicle stimulating hormone. J Clin Endocrinol Metab 1978, 47:263-267.
18. Suzuki T, Sasano H, Tamura M, et al.: Temporal and spatial localization of steroidogenic enzymes in premenopausal human ovaries: in situ hybridization and immunohistochemical study. Mol Cell Endocrinol 1993, 97:135-143.
19. Kiriakidou M, McAllister J, Sugarwara T, et al.: Expression of steroidogenic acute regulatory protein (StAR) in the human ovary. J Clin Endocrinol Metab 1996, 81:4122-4128.
20. Sugawara T, Holt J, Kiriakidou M, et al.: Steroidogenic factor-1-dependent promoter activity of the human steroidogenic acute regulatory protein (StAR) gene. Biochemistry 1996, 35:9052-9059.
21. McAllister J, Simpson E: Human theca interna cells in culture. In Methods in Toxicology. Edited by Heindel, J and Chapin, R. San Diego: Academic Press; 1993:330-339.
22. McAllister J, Kerin J, Trant J, et al.: Regulation of cholesterol side-chain cleavage and 17α-hydroxylase/lyase activities in proliferating theca interna cells in long term monolayer culture. Endocrinol 1989, 125:1959-1966.
23. Nelson VL, Qin Kn KN, Rosenfield RL, et al.: The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86:5925-5933. These findings indicate tissue-specific expression of aldoketoreductase family members and suggest that testosterone production in PCOS theca cells does not result from dysregulation of "androgenic" 17βHSD activity or altered expression of AKRs that may express 17βHSD activity, but rather from increased androgen precursor production.
24. Barbieri R, Makis A, Randall R, et al.: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986, 62:904-910.
25. Nestler JE, Jakubowicz DJ, de Vargas AF, et al.: Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998, 83:2001-2005.
26. Barnes R, Rosenfield R, Burnstein S, et al.: Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989, 320:559-565.
27. Jakubowicz D, Nestler J: 17α-Hydroxyprogesterone response to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997, 82:556-559.
28. Gilling-Smith C, Storey H, Rogers V, et al.: Evidence for a primary abnormality in theca cell steroidogenesis in the polycystic ovarian syndrome. Clin Endocrinol 1997, 47:1158-1165.
29. Katulski K, Bornstein S, Figiel M, et al.: Typical hormonal profiles are accompanied by increased immunoreactivity of theca folliculi steroi 17 alpha-hydroxylase P450 in polycystic ovary syndrome. J Endocrinol Invest 1998, 21:304-309.
30. Tamura T, Kitawaki J, Yamamoto T, et al.: Immunohistochemical localization of 17α-hydroxylase/C17-20 lyase and aromatase cytochrome P-450 in polycystic human ovaries. J Endocrinol 1993, 139:503-509.
31. Gilling-Smith C, Willis DS, Beard RW, et al.: Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994, 79:1158-1165.
32. Wickenheisser JK, Quinn PG, Nelson VL, et al.: Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 2000, 85:2304-2311. By comparison of CYP17 and STAR promoter activity in normal and PCOS theca cells, these studies established that alterations in CYP17 gene transcription, at the level of the CYP17 promoter regulation, contribute to increased CYP17 gene expression in PCOS.
33. Strauss JF, Wood JR, Christenson LK, et al.: Strategies to elucidate the mechanism of excessive theca cell androgen production in PCOS. Mol Cell Endocrinol 2002, 186:183-188. This report describes molecular strategies to identify differentially transcribed genes in PCOS theca cells.
34. Jakimiuk AJ, Weitsman SR, Navab A, et al.: Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001, 86:1318-1323. This study examined the gene expression of steroidogenic enzymes in tissue specimens obtain from normal and PCOS ovary and showed that LH receptor, StAR, CYP17, and CYP11A mRNA expression are elevated in PCOS theca cells thereby further demonstrating that steroidogenic enzyme mRNAs are overexpressed in thecal cells from polycystic ovaries.
35. Jakimiuk AJ, Weitsman SR, Magoffin DA: 5alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1999, 84:2414-2418. This report compares 5α-reductase activity and expression in freshly isolated ovarian cells from normal cycling and PCOS women.
36. Gharani N, Waterworth DM, Batty S, et al.: Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997, 6:397-402.
37. Diamanti-Kandarakis E, Bartzis M, Zapanti E, et al.: Polymorphism T->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999, 71:431-435.
38. Gharani N, Waterworth DM, Williamson R, et al.: 5′ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries [letter]. J Clin Endocrinol Metab 1996, 81:4174-4175.
39. Daneshmand S, Weitsman SR, Navab A, et al.: Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C(17-20) lyase promoters. Fertil Steril 2002, 77:274-280. Genotyping of the promoters of the CYP17 and CYP11A genes in normal and PCOS patients has confirmed that previously identified polymorphic regions do not correlate with increased expression of CYP17 and CYP11A in PCOS.
40. Marszalek B, Lacinski M, Babych N, et al.: Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome. Gynecological Endocrinology 2001, 15:123-128.
41. Urbanek M, Legro, RS, Driscoll, DA, et al.: Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999, 96:8573-8578.
42. Nayak S, Lee PA, Witchel SF: Variants of the type II 3beta-hydroxysteroid dehydrogenase gene in children with premature pubic hair and hyperandrogenic adolescents. Mol Genet Metab 1998, 64:184-192.
43. Azziz R, Bradley Jr E, Potter H, et al.: 3 beta-hydroxysteroid dehydrogenase deficiency in hyperandrogenism. Am J Obstet Gynecol 1993, 168:889-895.
44. Asplin I, Galasko G, Larner J: chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 1993, 90:5924-5928.
45. Larner J, Allan G, Kessler C, et al.: Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. J Basic Clin Physiol Pharmacol 1998, 9:127-137.
46. Nestler JE, Jakubowicz DJ, Reamer P, et al.: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999, 340:1314-1320.
47. Willis D, Franks S: Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995, 80:3788-3790.
48. Willis D, Mason H, Gilling-Smith C, et al.: Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996, 81:302-309.
49. Wu X, Sallinen K, Anttila L, et al.: Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls. Fertil Steril 2000, 74:564-572.
50. Attia GR, Rainey WE, Carr BR: Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001, 76:517-524. This study demonstrates that the insulin sensitizing drug metformin inhibits androstenedione production and CYP17 mRNA expression in cultured theca cells, which suggests that treatment with insulin-sensitizing agents may have a direct effect on ovarian androgen biosynthesis.
51. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450C17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335:617-623.
52. Nestler JE, Jakubowicz DJ, Iuorno MJ: Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Metab 2000, 13(Suppl 5):1295-1298.
53. Nestler JE: Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions. J Basic Clin Physiol Pharmacol 1998, 9:197-204.
54. Sleight S, Wilson BA, Heimark DB, et al.: G(q/11) is involved in insulin-stimulated inositol phosphoglycan putative mediator generation in rat liver membranes: co-localization of G(q/11) with the insulin receptor in membrane vesicles. Biochem Biophys Res Commun 2002, 295:561-569.
55. Larner J: D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002, 3:47-60.
56. Loffler S, Aust G, Kohler U, et al.: Evidence of leptin expression in normal and polycystic human ovaries. Mol Hum Reprod 2001, 7:1143-1149.
57. Shalev E, Goldman S, Ben-Shlomo I: The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP)-1 in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. Mol Hum Reprod 2001, 7:325-331.
58. Atiomo WU, Hilton D, Fox R, et al.: Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries. Gynecological Endocrinology 2000, 14:162-168.
59. Cataldo NA, Dumesic DA, Goldsmith PC, et al.: Immunolocalization of Fas and Fas ligand in the ovaries of women with polycystic ovary syndrome: relation to apoptosis. Hum Reprod 2000, 15:1889-1897.
60. Fujiwara T, Sidis Y, Welt C, et al.: Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. J Clin Endocrinol Metab 2001, 86:4206-4215.
61. Almahbobi G, Misajon A, Hutchinson P, et al.: Hyperexpression of epidermal growth factor receptors in granulosa cells from women with polycystic ovary syndrome. Fertil Steril 1998, 70:750-758.
62. Teixeira Filho FL, Baracat EC, Lee TH, et al.: Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:1337-1344. Evidence is provided in this report that dysregulation of oocyte GDF-9 expression may play a role in abnormal follicular development in PCOS and PCO women.
63. Yamamoto N, Christenson LK, McAllister JM, et al.: Growth differentiation factor-9 inhibits 3′5′-adenosine monophosphate-stimulated steroidogenesis in human granulosa and theca cells. J Clin Endocrinol Metab 2002, 87:2849-2856. This report implicates GDF-9 as a modulator of follicular steroidogenesis by its ability to inhibit 17α-hydroxprogesterone and DHEA production in propagated theca cells.
64. Lunn SF, Fraser HM, Mason HD: Structure of the corpus luteum in the ovulatory polycystic ovary. Hum Reprod 2002, 17:111-117.
65. Ledee-Bataille N, Lapree-Delage G, Taupin JL, et al.: Follicular fluid concentration of leukaemia inhibitory factor is decreased among women with polycystic ovarian syndrome during assisted reproduction cycles. Hum Reprod 2001, 16:2073-2078.
66. Lass A, Weiser W, Munafo A, et al.: Leukemia inhibitory factor in human reproduction. Fertil Steril 2001, 76:1091-1096.
67. Cook CL, Siow Y, Brenner AG, et al.: relation between serum Mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002, 77:141-146.
68. Fallat ME, Siow Y, Marra M, et al.: Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril 1997, 67:962-965.
69. Naz RK, Thurston D, Santoro N: Circulating tumor necrosis factor (TNF)-alpha in normally cycling women and patients with premature ovarian failure and polycystic ovaries. Am J Reprod Immunol (Copenhagen) 1995, 34:170-175.